换一批Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosing.
第一作者：
Vivian G,Oehler
第一单位：
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA. voehler@fredhutch.org.
作者：
医学主题词
人类(Humans);蛋白激酶抑制剂(Protein Kinase Inhibitors);白血病, 髓系, 慢性, BCR-ABL阳性(Leukemia, Myelogenous, Chronic, BCR-ABL Positive);抗肿瘤药(Antineoplastic Agents);疾病管理(Disease Management);融合蛋白质类, bcr-abl(Fusion Proteins, bcr-abl);蛋白酪氨酸激酶类(Protein-Tyrosine Kinases)
DOI
10.3324/haematol.2025.288334
PMID
41816837
发布时间
2026-07-01
- 浏览0
Haematologica
2266-2280页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
